Sonoma Pharmaceuticals (SNOA) said late Monday the US Food and Drug Administration has granted a new 510(k) clearance for its Microcyn technology-based hydrogel for wound treatment.
The clearance allows the product to be used, under the supervision of a healthcare professional, for wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, first and second degree burns, diabetic ulcers, and mechanically or surgically-debrided wounds, the company said.
The clearance applies to 50 milliliter bottles with a shelf life of 24 months, it said.
Price: 2.9600, Change: -0.14, Percent Change: -4.52
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。